Prostaglandin e receptor subtype 4 signaling in the heart: Role in ischemia/reperfusion injury and cardiac hypertrophy

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Pang, Lei ^a   Cai, Yin ^b   Tang, Eva Hoi Ching ^b,c   Irwin, Michael G ^b   Ma, Haichun ^a   Xia, Zhengyuan ^b  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2;

HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; KNOCKOUT MOUSE; NONHUMAN; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; DINOPROSTONE; HUMANS; MICE; MYOCARDIUM; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84967154799     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1324347     Document Type: Review

References (85)

1. P. Ferdinandy, D. J. Hausenloy, G. Heusch, G. F. Baxter, and R. Schulz, "Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning, " Pharmacological Reviews, vol. 66, no. 4, pp. 1142-1174, 2014.
2. E. E. Calle, M. J. Thun, J. M. Petrelli, C. Rodriguez, and C. W. Heath Jr., "Body-mass index and mortality in a prospective cohort of U. S. adults, "The New England Journal of Medicine, vol. 341, no. 15, pp. 1097-1105, 1999.
3. S. Yusuf, S. Hawken, S. Ôunpuu et al., "Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study, " The Lancet, vol. 366, no. 9497, pp. 1640-1649, 2005.
4. Z. C. Berwick, G. M. Dick, and J. D. Tune, "Heart of the matter: coronary dysfunction in metabolic syndrome, " Journal of Molecular and Cellular Cardiology, vol. 52, no. 4, pp. 848-856, 2012.
5. H. Li, W. Yao, M. G. Irwin et al., "Adiponectin ameliorates hyperglycemia-induced cardiac hypertrophy and dysfunction by concomitantly activatingNrf2 and Brg1, " Free Radical Biology and Medicine, vol. 84, pp. 311-321, 2015.
6. S. S. Martin, A. Qasim, and M. P. Reilly, "Leptin resistance: a possible interface of inflammation and metabolism in obesityrelated cardiovascular disease, " Journal of the American College of Cardiology, vol. 52, no. 15, pp. 1201-1210, 2008.
7. M. Ng, T. Fleming, M. Robinson et al., "Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013, " The Lancet, vol. 384, no. 9945, pp. 766-781, 2014.
8. D. V. D. Poorten, Obesity, gastrointestinal cancer and the role of visceral fat, Translational Gastrointestinal Cancer, vol. 3, no. 3, pp. 127129, 2014.
9. M. Murakami, "Lipid mediators in life science, " Experimental Animals, vol. 60, no. 1, pp. 7-20, 2011.
10. M. A. Gijón and C. C. Leslie, "Regulation of arachidonic acid release and cytosolic phospholipase A2 activation, " Journal of Leukocyte Biology, vol. 65, no. 3, pp. 330-336, 1999.
11. H. Harizi, J.-B. Corcuff, and N. Gualde, "Arachidonic-acidderived eicosanoids: roles in biology and immunopathology, " Trends in Molecular Medicine, vol. 14, no. 10, pp. 461-469, 2008.
12. Y. Sugimoto and S. Narumiya, "Prostaglandin E receptors, " The Journal of Biological Chemistry, vol. 282, no. 16, pp. 11613-11617, 2007.
13. J. B. Regard, I. T. Sato, and S. R. Coughlin, "Anatomical profiling of G protein-coupled receptor expression, " Cell, vol. 135, no. 3, pp. 561-571, 2008.
14. E. H. C. Tang, Y. Cai, C. K. Wong et al., "Activation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue, " Journal of Lipid Research, vol. 56, no. 2, pp. 358-368, 2015.
15. C.-Y. Xiao, K.-I. Yuhki, A. Hara et al., "Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4, " Circulation, vol. 109, no. 20, pp. 2462-2468, 2004.
16. Y. Cai, F. Ying, E. Song et al., "Mice lacking prostaglandin E receptor subtype 4 manifest disrupted lipid metabolism attributable to impaired triglyceride clearance, " The FASEB Journal, vol. 29, no. 12, pp. 4924-4936, 2015.
17. E. H. C. Tang, K. Shimizu, T. Christen et al., "Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions, " Cardiovascular Research, vol. 89, no. 1, pp. 234-243, 2011.
18. E. H. C. Tang, E. Shvartz, K. Shimizu et al., "Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 2, pp. 261-269, 2011.
19. L. Bastien, N. Sawyer, R. Grygorczyk, K. M. Metters, and M. Adam, "Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype, " Journal of Biological Chemistry, vol. 269, no. 16, pp. 11873-11877, 1994.
20. B. K. Kobilka, "G protein coupled receptor structure and activation, " Biochimica et Biophysica Acta -Biomembranes, vol. 1768, no. 4, pp. 794-807, 2007.
21. S. Narumiya, Y. Sugimoto, and F. Ushikubi, "Prostanoid receptors: structures, properties, and functions, " Physiological Reviews, vol. 79, no. 4, pp. 1193-1226, 1999.
22. N. Tuteja, "Signaling through G protein coupled receptors, " Plant Signaling & Behavior, vol. 4, no. 10, pp. 942-947, 2009.
23. U. Yokoyama, K. Iwatsubo, M. Umemura, T. Fujita, and Y. Ishikawa, "The prostanoid EP4 receptor and its signaling pathway, " Pharmacological Reviews, vol. 65, no. 3, pp. 1010-1052, 2013.
24. M. P. Delghandi, M. Johannessen, and U. Moens, "The cAMP signalling pathway activates CREB through PKA, p38 andMSK1 in NIH 3T3 cells, " Cellular Signalling, vol. 17, no. 11, pp. 1343-1351, 2005.
25. T. Ichiki, "Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 449-455, 2006.
26. J. De Rooij, F. J. T. Zwartkruis, M. H. G. Verheijen et al., "Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP, " Nature, vol. 396, no. 6710, pp. 474-477, 1998.
27. H. Fujino and J. W. Regan, "EP4 prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein, " Molecular Pharmacology, vol. 69, no. 1, pp. 5-10, 2006.
28. M. B. Anand-Srivastava, "Modulation of Gi proteins in hypertension: role of angiotensin II and oxidative stress, " Current Cardiology Reviews, vol. 6, no. 4, pp. 298-308, 2010.
29. H. Fujino, K. A. West, and J. W. Regan, "Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2, " Journal of Biological Chemistry, vol. 277, no. 4, pp. 2614-2619, 2002.
30. S. Pugazhenthit, A. Nesterova, C. Sable et al., "Akt/protein kinase B up-regulates Bcl-2 expression throughcAMP-response element-binding protein, " Journal of Biological Chemistry, vol. 275, no. 15, pp. 10761-10766, 2000.
31. H. Fujino, W. Xu, and J. W. Regan, "Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases, "TheJournal of Biological Chemistry, vol. 278, no. 14, pp. 12151-12156, 2003.
32. K. Takayama, G. K. Sukhova, M. T. Chin, and P. Libby, "A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling, " Circulation Research, vol. 98, no. 4, pp. 499-504, 2006.
33. M. Minami, K. Shimizu, Y. Okamoto et al., "Prostaglandin E receptor type 4-associated protein interacts directly with NF-κB1 and attenuatesmacrophage activation, " Journal of Biological Chemistry, vol. 283, no. 15, pp. 9692-9703, 2008.
34. H. Katoh, A. Watabe, Y. Sugimoto, A. Ichikawa, and M. Negishi, "Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells, " Biochimica et Biophysica Acta, vol. 1244, no. 1, pp. 41-48, 1995.
35. Y. Naribayashi-Inomoto, M. Ding, H. Nakata et al., "Copresence of prostaglandin EP2 and EP3 receptors on gastric enterochromaffin-like cell carcinoid in African rodents, " Gastroenterology, vol. 109, no. 2, pp. 341-347, 1995.
36. D. J. Hausenloy and D. M. Yellon, "Myocardial ischemiareperfusion injury: a neglected therapeutic target, " Journal of Clinical Investigation, vol. 123, no. 1, pp. 92-100, 2013.
37. X. Mao, T. Wang, Y. Liu et al., "N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1α/HO-1 signaling in diabetic rats, " PLoS ONE, vol. 8, no. 7, Article IDe68949, 2013.
38. F. Heidrich, H. Schotola, A. F. Popov et al., "AMPK-activated protein kinase and its role in energy metabolism of the heart, " Current Cardiology Reviews, vol. 6, no. 4, pp. 337-342, 2010.
39. P. A. J. Krijnen, R. Nijmeijer, C. J. L. M. Meijer, C. A. Visser, C. E. Hack, and H. W. M. Niessen, "Apoptosis in myocardial ischaemia and infarction, " Journal of Clinical Pathology, vol. 55, no. 11, pp. 801-811, 2002.
40. N. G. Frangogiannis, "Targeting the inflammatory response in healing myocardial infarcts, " Current Medicinal Chemistry, vol. 13, no. 16, pp. 1877-1893, 2006.
41. L. Calabresi, G. Rossoni, M. Gomaraschi, F. Sisto, F. Berti, and G. Franceschini, "High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release, " Circulation Research, vol. 92, no. 3, pp. 330-337, 2003.
42. G. L. Semenza, "Hypoxia-inducible factor 1 and cardiovascular disease, " Annual Review of Physiology, vol. 76, pp. 39-56, 2014.
43. A. Kaidi, D. Qualtrough, A. C. Williams, and C. Paraskeva, "Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia, " Cancer Research, vol. 66, no. 13, pp. 6683-6691, 2006.
44. J. He, M. Wang, Y. Jiang et al., "Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a-5p/HIF-1α/COX-2 pathway, " Environmental Health Perspectives, vol. 122, no. 3, pp. 255-261, 2014.
45. K. Schrör, K. C. Zimmermann, and R. Tannhäuser, "Augmented myocardial ischaemia by nicotine-mechanisms and their possible significance, " British Journal of Pharmacology, vol. 125, no. 1, pp. 79-86, 1998.
46. A. Abbate, D. Santini, G. G. L. Biondi-Zoccai et al., "Cyclooxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?" Heart, vol. 90, no. 4, pp. 440-443, 2004.
47. K. Hishikari, J.-I. Suzuki, M. Ogawa et al., "Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury, " Cardiovascular Research, vol. 81, no. 1, pp. 123-132, 2009.
48. Z. Cai, H. Zhong, M. Bosch-Marce et al., "Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1α, " Cardiovascular Research, vol. 77, no. 3, pp. 463-470, 2008.
49. R. S. Adluri, M. Thirunavukkarasu, N. R. Dunna et al., "Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice, " Antioxidants & Redox Signaling, vol. 15, no. 7, pp. 1789-1797, 2011.
50. R. Bolli, K. Shinmura, X.-L. Tang et al., "Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning, " Cardiovascular Research, vol. 55, no. 3, pp. 506-519, 2002.
51. Y. Wang, E. Kodani, J. Wang et al., "Cardioprotection during the final stage of the late phase of ischemic preconditioning ismediated by neuronal NO synthase in concert with cyclooxygenase-2, " Circulation Research, vol. 95, no. 1, pp. 84-91, 2004.
52. K. Leineweber, M. Böhm, and G. Heusch, "Cyclic adenosine monophosphate in acute myocardial infarction with heart failure: slayer or savior?" Circulation, vol. 114, no. 5, pp. 365-367, 2006.
53. T. Takahashi, T. Tang, N. C. Lai et al., "Increased cardiac adenylyl cyclase expression is associatedwith increased survival aftermyocardial infarction, " Circulation, vol. 114, no. 5, pp. 388-396, 2006.
54. K. Birkenmeier, I. Janke, W.-H. Schunck et al., "Prostaglandin receptors mediate effects of substances released fromischaemic rat hearts on non-ischaemic cardiomyocytes, " European Journal of Clinical Investigation, vol. 38, no. 12, pp. 902-909, 2008.
55. Y. Oshima, Y. Fujio, T. Nakanishi et al., "STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart, " Cardiovascular Research, vol. 65, no. 2, pp. 428-435, 2005.
56. G. Heusch, J. Musiolik, N. Gedik, and A. Skyschally, "Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/ reperfusion, " Circulation Research, vol. 109, no. 11, pp. 1302-1308, 2011.
57. M. A. Frias, M. C. Rebsamen, C. Gerber-Wicht, and U. Lang, "Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy, " Cardiovascular Research, vol. 73, no. 1, pp. 57-65, 2007.
58. M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour, and U. Lang, "The PGE2-Stat3 interaction in doxorubicininduced myocardial apoptosis, " Cardiovascular Research, vol. 80, no. 1, pp. 69-77, 2008.
59. H. Nishihara, S. Kizaka-Kondoh, P. A. Insel, and L. Eckmann, "Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8921-8926, 2003.
60. A. Akram, C. L. Gibson, and B. D. Grubb, "Neuroprotection mediated by the EP4 receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury, " Neuropharmacology, vol. 65, pp. 165-172, 2013.
61. R. B. Devereux, D. D. Savage, I. Sachs, and J. H. Laragh, "Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension, " The American Journal of Cardiology, vol. 51, no. 1, pp. 171-176, 1983.
62. 1 and endothelin-1 from fibroblasts, " Cardiovascular Research, vol. 40, no. 2, pp. 352-363, 1998.
63. G. G. N. Serneri, P. A. Modesti, M. Boddi et al., "Cardiac growth factors in human hypertrophy: relations with myocardial contractility and wall stress, " Circulation Research, vol. 85, no. 1, pp. 57-67, 1999.
64. S. Fredj, J. Bescond, C. Louault, A. Delwail, J.-C. Lecron, and D. Potreau, "Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions duringmyocyte hypertrophy and fibroblast proliferation, " Journal of Cellular Physiology, vol. 204, no. 2, pp. 428-436, 2005.
65. N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill, "Hypertrophy of the heart: a new therapeutic target?" Circulation, vol. 109, no. 13, pp. 1580-1589, 2004.
66. Q. He, P. Harding, and M. C. LaPointe, "PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 1, pp. H136-H143, 2010.
67. S. Miyatake, H. Manabe-Kawaguchi, K. Watanabe, S. Hori, N. Aikawa, and K. Fukuda, "Prostaglandin E2 induces hypertrophic changes and suppresses α-skeletal actin gene expression in rat cardiomyocytes, " Journal of Cardiovascular Pharmacology, vol. 50, no. 5, pp. 548-554, 2007.
68. J.-Y. Qian, A. Leung, P. Harding, and M. C. LaPointe, "PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44MAPK, "American Journal of Physiology-Heart and Circulatory Physiology, vol. 290, no. 5, pp. H1740-H1746, 2006.
69. M. C. LaPointe, M. Mendez, A. Leung, Z. Tao, and X.-P. Yang, "Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 286, no. 4, pp. H1416-H1424, 2004.
70. N. Degousee, S. Fazel, D. Angoulvant et al., "Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction, " Circulation, vol. 117, no. 13, pp. 1701-1710, 2008.
71. J.-Y. Qian, P. Harding, Y. Liu, E. Shesely, X.-P. Yang, and M. C. LaPointe, "Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction, " Hypertension, vol. 51, no. 2, pp. 560-566, 2008.
72. A. Hara, K.-I. Yuhki, T. Fujino et al., "Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor, " Circulation, vol. 112, no. 1, pp. 84-92, 2005.
73. E. H. C. Tang, P. Libby, P. M. Vanhoutte, and A. Xu, "Antiinflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases, " Journal of Cardiovascular Pharmacology, vol. 59, no. 2, pp. 116-123, 2012.
74. M. F. Allard, "Energy substratemetabolism in cardiac hypertrophy, " Current Hypertension Reports, vol. 6, no. 6, pp. 430-435, 2004.
75. P. J. H. Smeets, B. E. J. Teunissen, A. Planavila et al., "Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARα and PPARδ, "The Journal of Biological Chemistry, vol. 283, no. 43, pp. 29109-29118, 2008.
76. W. Soesanto, H.-Y. Lin, E. Hu et al., "Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats, " Hypertension, vol. 54, no. 6, pp. 1321-1327, 2009.
77. H. H. Chang, S. H. Young, J. Sinnett-Smith et al., "Prostaglandin E2 activates themTORC1 pathway through an EP4/cAMP/PKAand EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1, " American Journal of Physiology-Cell Physiology, vol. 309, no. 10, pp. C639-C649, 2015.
78. M. Métrich, M. Berthouze, E. Morel, B. Crozatier, A. M. Gomez, and F. Lezoualch, "Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology, " Pflugers Archiv European Journal of Physiology, vol. 459, no. 4, pp. 535-546, 2010.
79. M. Mendez and M. C. LaPointe, "PGE2-induced hypertrophy of cardiacmyocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 288, no. 5, pp. H2111-H2117, 2005.
80. B. A. Rose, T. Force, and Y. Wang, "Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heartbreaking tale, " Physiological Reviews, vol. 90, no. 4, pp. 1507-1546, 2010.
81. N. Prenzel, E. Zwick, H. Daub et al., "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF, " Nature, vol. 402, no. 6764, pp. 884-888, 1999.
82. B. H. Shah, M. P. Farshori, A. Jambusaria, and K. J. Catt, "Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropinreleasing hormone receptor activation, " Journal of Biological Chemistry, vol. 278, no. 21, pp. 19118-19126, 2003.
83. K. Kunisada, S. Negoro, E. Tone et al., "Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicininduced cardiomyopathy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 1, pp. 315-319, 2000.
84. K. Kunisada, E. Tone, Y. Fujio, H. Matsui, K. Yamauchi-Takihara, and T. Kishimoto, "Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes, " Circulation, vol. 98, no. 4, pp. 346-352, 1998.
85. H. Xiong, W. Du, T.-T. Sun et al., "A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis, " International Journal of Cancer, vol. 134, no. 9, pp. 2030-2040, 2014.